TL;DR: The Centers for Medicare & Medicaid Services modified NCD 156 governing intravenous iron therapy for hemodialysis patients, with an effective date of March 7, 2026. Here's what billing teams need to know.
This update to the CMS intravenous iron therapy coverage policy confirms Medicare coverage for two specific IV iron products — sodium ferric gluconate complex in sucrose injection and iron sucrose injection — as first-line treatment for iron deficiency anemia in chronic hemodialysis patients receiving erythropoietin therapy. NCD 156 is the National Coverage Determination that governs this benefit under the Medicare Drugs and Biologicals benefit category. The policy does not list specific HCPCS codes in the current document, so your charge capture approach requires particular attention.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Intravenous Iron Therapy — NCD 156 |
| Policy Code | NCD 156 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium |
| Specialties Affected | Nephrology, dialysis facilities, renal care billing teams, ESRD programs |
| Key Action | Confirm your dialysis facility's charge capture aligns with the two covered IV iron products and the dual coverage criteria: chronic hemodialysis plus active erythropoietin therapy |
CMS Intravenous Iron Therapy Coverage Criteria and Medical Necessity Requirements 2026
NCD 156 covers IV iron therapy for a specific, narrow population. Get the two criteria wrong on a single claim, and you're looking at a claim denial.
The two covered IV iron products under this coverage policy are sodium ferric gluconate complex in sucrose injection (covered effective December 1, 2000) and iron sucrose injection (covered effective October 1, 2001). Both are covered as first-line treatment only. That designation matters — if a patient received oral iron first and it failed, document that clearly before billing IV iron as first-line.
Both of these conditions must be met to satisfy medical necessity:
| # | Covered Indication |
|---|---|
| 1 | The patient is undergoing chronic hemodialysis. |
| 2 | The patient is receiving supplemental erythropoietin therapy. |
These aren't soft criteria. CMS language says "when furnished intravenously to patients undergoing chronic hemodialysis who are receiving supplemental erythropoietin therapy." That "and" is doing a lot of work. A patient on hemodialysis who is not actively on erythropoietin therapy does not meet the medical necessity standard under NCD 156. Document both conditions in the medical record before the date of service.
The clinical rationale behind the coverage policy is sound. IV iron bypasses the GI absorption problems that make oral iron unreliable in ESRD patients. It goes directly into the bloodstream in a form the bone marrow can use immediately for red blood cell synthesis. CMS recognized this back in 2000 and 2001 when it established the original coverage dates. This 2026 modification carries those coverage criteria forward.
The policy does not mention prior authorization requirements for IV iron therapy under NCD 156. That said, your Medicare Administrative Contractor may have issued a local coverage determination that layers additional requirements on top of this NCD. Check with your MAC before assuming prior authorization is not needed at the regional level.
Reimbursement for these products falls under the ESRD bundled payment system for most dialysis facilities. That's a separate billing issue from coverage, but it affects how you report the drug administration. If you're billing outside the bundle — for example, in a hospital outpatient setting — your billing guidelines will differ. Know your setting before you submit.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Iron deficiency anemia — chronic hemodialysis patient on erythropoietin therapy — sodium ferric gluconate complex in sucrose injection (IV) | Covered | Not listed in NCD 156 document | Covered effective December 1, 2000; first-line designation required |
| Iron deficiency anemia — chronic hemodialysis patient on erythropoietin therapy — iron sucrose injection (IV) | Covered | Not listed in NCD 156 document | Covered effective October 1, 2001; first-line designation required |
| IV iron therapy for ESRD patient NOT on erythropoietin therapy | Not covered under NCD 156 | N/A | Both criteria must be met; erythropoietin therapy is required |
| Oral iron supplementation for hemodialysis patients | Not addressed | N/A | NCD 156 covers IV administration only |
| IV iron for non-ESRD indications | Not addressed | N/A | NCD 156 is specific to chronic hemodialysis patients |
CMS Intravenous Iron Therapy Billing Guidelines and Action Items 2026
The policy modification is dated March 7, 2026. Here's what your billing team should do now.
| # | Action Item |
|---|---|
| 1 | Audit your documentation standards before submitting claims dated on or after March 7, 2026. Every IV iron claim under NCD 156 needs two things in the record: confirmation of chronic hemodialysis status and confirmation of active erythropoietin therapy. If your facility's intake documentation doesn't capture both, fix that now. |
| 2 | Confirm which IV iron products your facility uses. NCD 156 covers sodium ferric gluconate complex in sucrose and iron sucrose. Other IV iron products — ferumoxytol, ferric carboxymaltose, low molecular weight iron dextran — are not addressed in this NCD. If your formulary has shifted to a newer agent, verify coverage through your MAC's local coverage determination before billing. |
| 3 | Check your MAC's LCD for any regional additions. NCD 156 sets the floor. Your Medicare Administrative Contractor may have a local coverage determination that adds documentation requirements, prior authorization steps, or frequency limits. Pull the LCD for your jurisdiction and compare it against NCD 156 before the effective date. |
| 4 | Review your ESRD bundle billing for drug inclusion. For most dialysis facilities, IV iron is bundled into the ESRD prospective payment system. Billing it separately when it's already included in the bundle is a fast path to a claim denial and a potential overpayment issue. Confirm with your billing consultant how your facility handles bundled versus separately billable drug administration. |
| 5 | Flag the missing HCPCS codes as a workflow gap. The NCD 156 document does not list specific HCPCS codes. Your team is billing these products under codes your charge master already has — likely Q-codes or J-codes for the specific iron products. Make sure those codes are mapped correctly to the covered drug names in the policy. If you're not certain which HCPCS codes correspond to sodium ferric gluconate complex in sucrose or iron sucrose under your MAC, contact your MAC directly or loop in your billing consultant before the March 7, 2026 effective date. |
| 6 | Don't bill IV iron as first-line if oral iron was tried first — without documentation. The policy designates IV iron as a first-line treatment. If oral iron was tried and failed, you need that documented before claiming first-line status. "First-line" in CMS policy language is not just a clinical choice — it's a coverage condition. |
The real issue with intravenous iron therapy billing isn't the coverage logic. It's the documentation. The criteria are narrow and clear. Claims fail because the record doesn't prove both conditions at the time of service. Build a checklist into your pre-billing workflow that requires both the hemodialysis status and the erythropoietin therapy confirmation before a claim goes out.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Intravenous Iron Therapy Under NCD 156
The NCD 156 policy document does not list specific CPT, HCPCS, or ICD-10 codes. This is a gap in the source document, not an error in this summary.
What This Means for Intravenous Iron Therapy Billing
Your team is already using HCPCS codes to bill these products — the NCD document simply doesn't enumerate them. The two drugs covered under NCD 156 are sodium ferric gluconate complex in sucrose injection and iron sucrose injection. Your charge master should have HCPCS codes mapped to those specific drug names.
Contact your MAC's provider relations line if you need confirmation on which HCPCS codes your jurisdiction maps to these products. Do not assume the codes in your charge master are correct without verifying against current HCPCS guidance — drug HCPCS codes do change, and a mismatch between the drug billed and the code submitted is a straightforward claim denial.
For ICD-10 diagnosis coding, iron deficiency anemia in ESRD patients is typically documented under codes in the D50 range (iron deficiency anemias) combined with ESRD and chronic kidney disease codes in the N18 range. Your clinical documentation should support the specific anemia and ESRD diagnosis codes your coder selects. If you're unsure how to align the diagnosis coding with NCD 156 criteria, talk to your compliance officer before the effective date.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.